1. Inici
  2. Publicacions
  3. Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry

Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry

Data de publicació: Data Ahead of Print:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Torres-Pena, JD
  • Perez-Belmonte, LM
  • Fuentes-Jimenez, F
  • Carmona, MDL
  • Perez-Martinez, P
  • Lopez-Miranda, J
  • Sanchez, FJC
  • Nunez, JAV
  • Beamonte, ED
  • Gamboa, JOM
  • Garcia, AG
  • Moraleja, JG
  • Troncoso, AC
  • Martinez, MLT
  • Montero, MDD
  • Ripol, JMS
  • Gonzalez, DA
  • Boixeda, R
  • Rodriguez, BC
  • Ena, J
  • Garcia, GMG
  • Esteve, AV
  • Rincon, JMR
  • Gomez-Huelgas, R

Grups d'Investigació

Abstract

Background The impact of statins on COVID-19 outcomes is important given the high prevalence of their use among individuals at risk for severe COVID-19. Our aim is to assess whether patients receiving chronic statin treatment who are hospitalized with COVID-19 have reduced in-hospital mortality if statin therapy is maintained during hospitalization. Methods This work is a cross-sectional, observational, retrospective multicenter study that analyzed 2921 patients who required hospital admission at 150 Spanish centers included in the nationwide SEMI-COVID-19 Network. We compared the clinical characteristics and COVID-19 disease outcomes between patients receiving chronic statin therapy who maintained this therapy during hospitalization versus those who did not. Propensity score matching was used to match each statin user whose therapy was maintained during hospitalization to a statin user whose therapy was withdrawn during hospitalization. Results After propensity score matching, continuation of statin therapy was associated with lower all-cause mortality (OR 0.67, 0.54-0.83, p < 0.001); lower incidence of acute kidney injury (AKI) (OR 0.76,0.6-0.97, p = 0.025), acute respiratory distress syndrome (ARDS) (OR 0.78, 0.69- 0.89, p < 0.001), and sepsis (4.82% vs 9.85%, p = 0.008); and less need for invasive mechanical ventilation (IMV) (5.35% vs 8.57, p < 0.001) compared to patients whose statin therapy was withdrawn during hospitalization. Conclusions Patients previously treated with statins who are hospitalized for COVID-19 and maintain statin therapy during hospitalization have a lower mortality rate than those in whom therapy is withdrawn. In addition, statin therapy was associated with a decreased probability that patients with COVID-19 will develop AKI, ARDS, or sepsis and decreases the need for IMV.

Dades de la publicació

ISSN/ISSNe:
0012-6667, 1179-1950

Drugs  Adis International Ltd.

Tipus:
Article
Pàgines:
685-695
PubMed:
33782908
Factor d'Impacte:
2,081 SCImago ℠
Quartil:
Q1 SCImago ℠

Cites Rebudes en Web of Science: 26

Documents

  • No hi ha documents

Mètriques

Filiacions mostrar / ocultar

Keywords

  • ENDOTHELIAL FUNCTION; LOWERING THERAPY; CORONARY

Projectes associats

SUBREGISTRO PROSPECTIVO, MULTICÉNTRICO Y OBSERVACIONAL DE SEGURIDAD POSTAUTORIZACIÓN PARA CARACTERIZAR EL PERFIL DE SEGURIDAD A LARGO PLAZO DEL USO COMERCIAL DE ELIGLUSTAT (CERDELGA®) EN PACIENTES ADULTOS CON ENFERMEDAD DE GAUCHER.

Investigador Principal: PATRICIA CORRECHER MEDINA

OBS14099 . 2018

MEMORIA PARA EL ESTUDIO DE ESPLENOMEGALIA Y PACIENTES ESPLENECTOMIZADOS NO FILIADOS EN POBLACIÓN INFANTIL Y ADULTA.

Investigador Principal: ISIDRO VITORIA MIÑANA

PREDIGA . 2020

Compartir la publicació